Welcome to the official Twitter page for Agios Medical Affairs. Here, we’ll be communicating our scientific information and latest developments in #RareDisease and #Hematology for HCPs. Not intended to provide medical advice. #AgiosMedical

Schedule a meeting with an Agios Medical Science Liaison (MSL) to learn about our hematology clinical developments and find out more about #AgiosMedical:

RT @thalassaemiaTIF: 📣 Big Announcement! The long-awaited 5th edition of the "TIF Guidelines for the Management of Transfusion Dependent…

Calling for research proposals. We are accepting applications for Agios Hemolytic Anemias Clinical Fellowship Competitive Grants to increase the number of skilled clinicians dedicated to classical #hematology and committed to providing comprehensive care for individuals living with hereditary hemolytic anemias including #SickleCell disease and #Thalassemia. Learn more and apply today by accessing the “Active RFAs/RFPs” tab: #AgiosMedical

Patients with #SickleCell disease have self-reported a significant burden on their daily lives. Explore the comprehensive Sickle Cell World Assessment Study (SWAY) results and impacts on quality of life found in our Education and Therapeutic Management resource: #AgiosMedical

If you answered false, you’re correct! Transfusion frequency is not always a measure of underlying disease severity in #Thalassemia. The frequency and necessity of transfusions can change over time due to the recipient's age, biological changes, and non-biological factors. Review our thalassemia resources for more information: #AgiosMedical

True or false: Transfusion frequency is always a measure of underlying disease severity for #Thalassemia. #AgiosMedical

#Thalassemia can lead to a multitude of complications for patients. See the impact on patients in our resources:

RT @AgiosPharma: The @EU_Commission adopted a positive decision for the designation of our late-stage PK activator as an orphan medicinal p…

Join Dr. Jennifer Caudle and Dr. Samuel R. Wilson as we discuss the pathophysiology, clinical presentation, burden, and unmet needs of #SickleCell disease: #AgiosMedical #Hematology

It can be difficult to predict the potential complications due to the heterogeneity in clinical manifestations across #Thalassemia. Explore our thalassemia resources to learn more: #FastFacts #AgiosMedical

Thank you for joining us at #ASH24! See our latest research and advancements in #Thalassemia, #SickleCell disease, #MDS, and #PKDeficiency: #AgiosMedical #Hematology #ASH2024

See our recent #ASH24 publications for #Thalassemia and #MDS available in the Blood supplementary of November 2024: #AgiosMedical #ASH2024

Interested in learning more about our scientific data presented at #ASH24? Connect with a Medical Science Liaison (MSL): #AgiosMedical #ASH2024

Learn about Prof. Cappellini’s presentation on the clinical efficacy and safety data from our pivotal #Thalassemia study, ENERGIZE-T, at #ASH24: #AgiosMedical #ASH2024

Explore our presence at #ASH24 and discover our scientific data presentations for #Thalassemia, #SickleCell disease, #PKDeficiency, and #MDS. Learn more: #AgiosMedical #ASH2024

Our RISE UP Phase 2 clinical study results for #SickleCell disease have been published in @TheLancetHaem’s latest issue. See here: #AgiosMedical #Hematology

We’re looking forward to attending the 66th Annual @ASH_hematology conference next week. Follow along to learn about #AgiosMedical’s clinical data on #Thalassemia, #SickleCell disease, #PKDeficiency, and #MDS: #Hematology #ASH2024

Want to learn more about our clinical research and advancements? Stop by booth 105 at #ASH24 to speak with a member of the #AgiosMedical team. Learn more: #Hematology #RareDiseases #ASH2024

If you guessed true, you’re correct! Alpha- #Thalassemias are defined by an excess of β globin. View our resources for more thalassemia syndrome fast facts: #AgiosMedical

RT @AgiosPharma: At #ASH24, we’ll present new data and updates highlighting the clinical progress of our two PK activators in #thalassemia,…